Jose Andres Saez Fonseca1, Rhiannon Ducksbury2, Joanne Rodda3, Timothy Whitfield4, Chitra Nagaraj5, Kallur Suresh4, Tim Stevens4, Zuzana Walker4. 1. Department of Psychology,University of Roehampton,Roehampton Lane,London,SW15 5PU,UK. 2. Norfolk and Suffolk NHS Foundation Trust,Trust Headquarters,Hellesdon Hospital,Drayton High Road,Norwich,NR6 5BE,UK. 3. North East London NHS Foundation Trust,Trust Head Office,Goodmayes Hospital,Barley Lane,Ilford,Essex,IG3 8XJ,UK. 4. North Essex Partnership University NHS Foundation Trust,Trust Headquarters,Stapleford House,103 Stapleford Close,Chelmsford,Essex,CM2 0QX,UK. 5. Mersey Care NHS Trust,V7,Kings Business Park,Prescot,L34 1PJ,UK.
Abstract
BACKGROUND: Current evidence supports the concept of a preclinical phase of Alzheimer's disease (AD) where pathological and imaging changes are present in asymptomatic individuals. Subjective cognitive impairment (SCI) may represent the earliest point on the continuum of AD. A better understanding of the baseline characteristics of this group of patients that later decline in cognition will enhance our knowledge of the very early disease processes, facilitate preventive strategies, early diagnosis, timely follow-up and treatment. METHODS: An observational exploratory study which followed up 62 consecutive patients with SCI presenting to a memory clinic and compared baseline characteristics of SCI patients who declined cognitively with those who did not. Cognitive decline was defined as a progression to a diagnosis of amnestic mild cognitive impairment (aMCI) or dementia at follow-up. RESULTS: Patients were followed up for a mean of 44 months (range 12-112 months). At the time of follow up, 24% of patients had declined. Patients that declined were significantly older at onset of symptoms and first presentation to memory clinic, and took significantly more medications for physical illnesses. Patients that declined also performed significantly worse on Trail Making Test (TMT) B and Cambridge Cognitive Examination - Revised (CAMCOG-R) at baseline. Survival analysis identified key variables that predicted decline (later age of onset and later age at first assessment). CONCLUSIONS: Patients who present with subjective memory complaints and are over the age of 61 years are at high risk of cognitive decline and warrant an in-depth assessment and follow-up.
BACKGROUND: Current evidence supports the concept of a preclinical phase of Alzheimer's disease (AD) where pathological and imaging changes are present in asymptomatic individuals. Subjective cognitive impairment (SCI) may represent the earliest point on the continuum of AD. A better understanding of the baseline characteristics of this group of patients that later decline in cognition will enhance our knowledge of the very early disease processes, facilitate preventive strategies, early diagnosis, timely follow-up and treatment. METHODS: An observational exploratory study which followed up 62 consecutive patients with SCI presenting to a memory clinic and compared baseline characteristics of SCI patients who declined cognitively with those who did not. Cognitive decline was defined as a progression to a diagnosis of amnestic mild cognitive impairment (aMCI) or dementia at follow-up. RESULTS:Patients were followed up for a mean of 44 months (range 12-112 months). At the time of follow up, 24% of patients had declined. Patients that declined were significantly older at onset of symptoms and first presentation to memory clinic, and took significantly more medications for physical illnesses. Patients that declined also performed significantly worse on Trail Making Test (TMT) B and Cambridge Cognitive Examination - Revised (CAMCOG-R) at baseline. Survival analysis identified key variables that predicted decline (later age of onset and later age at first assessment). CONCLUSIONS:Patients who present with subjective memory complaints and are over the age of 61 years are at high risk of cognitive decline and warrant an in-depth assessment and follow-up.
Authors: Zvinka Z Zlatar; Martha C Muniz; Sarah G Espinoza; Roberto Gratianne; Tamar H Gollan; Douglas Galasko; David P Salmon Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Aldo Córdova-Palomera; Tobias Kaufmann; Karin Persson; Dag Alnæs; Nhat Trung Doan; Torgeir Moberget; Martina Jonette Lund; Maria Lage Barca; Andreas Engvig; Anne Brækhus; Knut Engedal; Ole A Andreassen; Geir Selbæk; Lars T Westlye Journal: Sci Rep Date: 2017-01-11 Impact factor: 4.379
Authors: Itziar de Rojas; J Romero; O Rodríguez-Gomez; P Pesini; A Sanabria; A Pérez-Cordon; C Abdelnour; I Hernández; M Rosende-Roca; A Mauleón; L Vargas; M Alegret; A Espinosa; G Ortega; S Gil; M Guitart; A Gailhajanet; M A Santos-Santos; Sonia Moreno-Grau; O Sotolongo-Grau; S Ruiz; L Montrreal; E Martín; E Pelejà; F Lomeña; F Campos; A Vivas; M Gómez-Chiari; M A Tejero; J Giménez; V Pérez-Grijalba; G M Marquié; G Monté-Rubio; S Valero; A Orellana; L Tárraga; M Sarasa; A Ruiz; M Boada Journal: Alzheimers Res Ther Date: 2018-11-29 Impact factor: 6.982
Authors: Hanneke F M Rhodius-Meester; Hilkka Liedes; Juha Koikkalainen; Steffen Wolfsgruber; Nina Coll-Padros; Johannes Kornhuber; Oliver Peters; Frank Jessen; Luca Kleineidam; José Luis Molinuevo; Lorena Rami; Charlotte E Teunissen; Frederik Barkhof; Sietske A M Sikkes; Linda M P Wesselman; Rosalinde E R Slot; Sander C J Verfaillie; Philip Scheltens; Betty M Tijms; Jyrki Lötjönen; Wiesje M van der Flier Journal: Alzheimers Dement (Amst) Date: 2018-10-08